Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb.
The treatment of soft tissue sarcoma of the limb by function-saving resection and brachytherapy (BRT) was systematically studied from 1975 to 1990 at the Memorial Sloan-Kettering Cancer Center, using iridium-192 temporary tumor-bed implants. Initial experiences showed an 88% local control rate in 33 patients who had locally advanced sarcomas, many of which would have required treatment by amputation. The technique also controlled 70% of tumors that abutted or invaded a major neurovascular bundle that was dissected out and preserved. A prospective randomized study (BRT vs no BRT) confirmed the highly significant efficacy of BRT in preventing local recurrence. This salutary effect is mainly seen in high-grade tumors. Major complications of wound healing occurred in the earlier years of this experience. Adoption of improved techniques of surgical wound repair, standardization of radiation dose planning, and in particular, postponing the loading of radiation sources until after the fifth postoperative day has reduced the rate of serious wound complications, to a level not significantly different from that seen after surgical resection alone. These results rival those currently achieved in centers experienced in external beam therapy of soft tissue sarcomas, and offer the advantage of completion of treatment in one relatively short hospital stay.
Shiu
M H
MH
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Hilaris
B S
BS
Harrison
L B
LB
Brennan
M F
MF
D000671:Amputation, Surgical; D001918:Brachytherapy / Q000009:adverse effects; D003131:Combined Modality Therapy; D005121:Extremities; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis
D007496:Iridium Radioisotopes